Study Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Want to learn more about this trial?
Request More InfoInterventions
CyclophosphamideDRUG
Administered intravenously
FludarabineDRUG
Administered intravenously
KITE-222BIOLOGICAL
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Stanford Cancer Center | Stanford | California | United States |
| Moffitt Cancer Center | Tampa | Florida | United States |
| Washington University School of Medicine | St Louis | Missouri | United States |
| Cleveland Clinic | Cleveland | Ohio | United States |
| The Ohio State University Wexner Medical Center/James Cancer Hospital | Columbus | Ohio | United States |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | United States |
| Fred Hutchinson Cancer Center | Seattle | Washington | United States |
| Institut Paoli-Calmettes | Marseille | France | |
| CHU de Toulouse Institut Universitaire du Cancer Toulouse Oncopole | Toulouse | France |